Pierre Benite

• Phase 2b Study of GSK4532990 in Adults with NASH (HORIZON) Ended
  2023-507503-62-00 4 2023-03-30 Non-alcoholic Fatty Liver Disease
• A Phase 2 Study of LTX-315 in Combination with Pembrolizumab in Patients with Advanced Melanoma Refractory to PD-1/PD-L1 Inhibitor Therapy ( … Ended
  2022-500628-31-00 4 2022-10-24 Advanced Melanoma
• Phase 1/2 Study of ZN-c3 and Niraparib and ZN-c3 Monotherapy in Platinum-Resistant Ovarian Cancer Ended
  2024-515196-35-00 3 2022-09-29 Platinum-Resistant Ovarian Cance
• A Phase 3 Study of Itolizumab in Combination with Corticosteroids for the Initial Treatment of Acute Graft Versus Host Disease (Complication … Ended
  2024-516064-28-00 5 2022-09-27 Acute Graft Versus Host Disease
• A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to dalteparin … Ended
  2024-513992-42-00 10 2022-09-13 venous thromboembolism (VTE) in patients with gastrointestinal/genitou
• A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to apixaban on … Ended
  2023-509569-19-00 10 2022-08-10 venous thromboembolism (VTE)
• A Study Evaluating Bemarituzumab in Solid Tumors with FGFR2b Overexpression Ended
  2023-505455-44-00 9 2022-06-29 Solid tumours
• Evaluation of MEpolizumab-based regimen Compared to Conventional Therapeutic Strategy For Remission Induction In Patients With Eosinophilic … Ended
  2024-513653-75-00 5 2022-05-30 Eosinophilic granulomatosis with polyangiitis (EGPA), formerly called
• A double-blind, placebo-controlled pilot trial of BP1.4979 for the treatment of binge eating disorder. Ended
  2023-506511-17-00 4 2022-03-07 Binge eating disorder
• A study to evaluate ExPEC9V vaccine for the prevention of Invasive E. coli Disease in adults aged 60 years and older with a history of urina … Ended
  2023-506589-30-00 5 2022-02-09 Invasive Extraintestinal Pathogenic Escherichia coli Disease
• Evaluating the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age Ended
  2023-508820-37-00 5 2022-02-03 Cytomegalovirus Infection (CMV)
• Study comparing the standard administration of immunotherapy (IO) versus the same agent administered each three months in patients with loca … Ended
  2024-513707-14-00 5 2022-01-14 Only patients with oncologic locally advanced or metastatic tumour (lu
• EvAluation of the efficacy of MaaT013 as salvage theRapy in acute GVHD patiEntS with gastrointestinal involvement, refractory to ruxolitinib … Ended
  2024-513023-17-00 5 2022-01-12 Treatment of acute graft-versus host disease (aGvHD) to the gastrointe
• An Open-Label, Phase 2 Trial of Nanatinostat in Combination with Valganciclovir in Patients with Epstein-Barr Virus-Positive (EBV+) Relapsed … Ended
  2024-512717-41-00 4 2021-10-01 Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas
• ASTX727 AND DONOR LYMPHOCYTE INFUSIONS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN VERY HIGH RISK MDS OR AML PATIENTS Ended
  2024-515353-24-00 4 2021-06-22 Patients with high risk myelodysplastic syndrome or acute myeloid leuk
• EASE SBS 3 (Evaluation of the efficacy and safety of Glepaglutide in the treatment of short bowel syndrome (SBS) Ended
  2024-513373-43-00 5 2021-06-11 Short bowel syndrome
• NIRAPK: Study of the relationships between pharmacokinetic properties (PK) and hematological toxicity of niraparib in ovarian cancer Ended
  2024-513856-14-00 6 2021-05-05 Patients with high-grade serous epithelial ovarian, tubal or primary p
• A first-in-human clinical trial in adult patients with advanced non-small cell lung cancer of a personalised therapy targeting specific muta … Ended
  2024-513060-26-00 7 2021-04-07 Non-small cell lung cancer
• EFRAIM II _ Empirical steroids and/or antifungals treatment of immunocompromised patients with acute respiratory failure of uknown origin: a … Ended
  2024-514344-82-00 5 2021-02-18 patients with acute respiratory failure from undetermined etiology
• A Phase 1, First-in-Human, Dose Escalation Study of the JNJ-75348780 Bispecific Antibody Targeting CD3 and CD22 in Participants with NHL and … Ended
  2023-504403-92-00 1 2021-02-15 Relapsed/refractory B-cell Non-Hodgkin Lymphoma (NHL) and Chronic Lymp
• A study to test Mirvetuximab Soravtansine (IMGN853) aganist doctor's choice of cancer medicines in women with advanced Epithelial Ovarian, P … Ended
  2024-516111-25-00 5 2020-11-09 Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Per
• Study to assess the efficacy and safety of alpelisib (BYL719) in combination with trastuzumab and pertuzumab as maintenance therapy in patie … Ended
  2024-512050-13-00 5 2020-09-22 HER2-positive advanced breast cancer
• A study to assess how radium-223 moves through the patients with prostate cancer receiving radium-223 dichloride treatment. Ended
  2023-506435-15-00 3 2020-08-25 Prostate cancer
• Phase II multicenter randomized trial evaluating the association of PIPAC and systemic chemotherapy versus systemic chemotherapy alone as 1s … Ended
  2024-515343-39-00 4 2020-08-14 Malignant Peritoneal Mesothelioma

Showing 361–384 of 404 trials